12 Vasoactives in 60 Seconds
View on Instagram
Sources and clarifications for this post
These are adult teaching summaries, not complete prescribing instructions. Receptor stars and repeated arrows are schematic, not validated numerical potency comparisons. BP, HR, SVR and CO responses depend on dose, loading conditions, cardiac function and reflex responses. The indication, route, preparation, monitoring and local protocol must accompany a drug dose. Overgaard and Džavík. Circulation 2008;118:1047–1056, physiology and comparison table.
Understanding the twelve vasoactives
1. Noradrenaline: “α1 ≫ β1”, 0.05–0.5 µg/kg/min, first-line sepsis/post-CPB.
Predominant vasoconstriction with some cardiac stimulation is a useful summary. BP and SVR usually rise, but the CO ↑ arrow is not assured: output can be unchanged or decrease, and reflex slowing of HR can occur. The dose strip is an illustrative infusion range, not a universal starting dose or maximum. Norepinephrine label, §§2.2 and 12; Overgaard and Džavík 2008, table p.1049.
Norepinephrine is first-line in septic shock. After cardiac surgery, the consensus supports norepinephrine and/or vasopressin, with vasopressin a possible first choice in pulmonary hypertension or right-heart dysfunction. “First-line” therefore does not describe one sequence for every post-bypass patient. SSC 2021, vasoactive agents; Guarracino et al. 2021, cardiac-surgery consensus.
2. Adrenaline: “arrest & anaphylaxis”, 0.01–0.5 µg/kg/min and IM 500 µg.
The α1/β1/β2 summary is sound, but SVR need not rise at low doses because β2 vasodilation can predominate. The infusion strip is not a dose for every indication: the cited adult septic-shock label uses 0.05–2 µg/kg/min, titrated to response. Epinephrine label, §§2.2 and 12.2.
The emergency doses belong to different routes and treatment settings. IM 500 µg is the RCUK adult anaphylaxis dose; paediatric doses differ. IV treatment of anaphylaxis is for experienced specialists in a monitored setting. Standard adult cardiac-arrest ALS uses 1 mg IV/IO with rhythm-specific timing and repeat dosing, not this infusion strip. RCUK anaphylaxis guidance, pp.29–34; RCUK adult ALS 2025.
A symbol is missing in the lactate line: the reel displays a box before “2”. The relevant mechanism is β2-receptor stimulation in skeletal muscle, which can increase lactate production even when oxygen is available. This can contribute to a lactate rise, but does not exclude poor perfusion; interpretation depends on the whole clinical picture. SSC 2021, vasoactive-agent rationale; epinephrine label, pharmacodynamics.
3. Vasopressin: 0.01–0.03 U/min, “do NOT titrate”, add at noradrenaline 0.25–0.5 µg/kg/min.
V1-mediated vasoconstriction and catecholamine sparing are supported, but V1 is not its only receptor action. HR and CO can fall despite the neutral arrows shown in the reel. The narrow dose strip describes a low-dose approach. The phrase “Do not titrate” reflects a fixed low-dose approach in sepsis, rather than a universal rule: the product label allows adjustment and distinguishes septic from post-cardiotomy shock. The norepinephrine threshold comes from a practice remark in SSC 2021, not a mandatory trigger independent of the pressure target. Vasopressin label, §§2.2, 5.1 and 12; SSC 2021, vasopressin recommendation and remark.
4. Phenylephrine: pure α1, CO →, bolus 50–100 µg, “ideal in HOCM / dynamic LVOTO”.
The α1 pressor mechanism, SVR/BP rise and possible reflex bradycardia are supported. CO is not reliably unchanged: it can fall, and heart failure may worsen. The 50–100 µg IV boluses are within the cited adult perioperative label and are its most commonly reported initial boluses; they are not the whole permitted range. Phenylephrine label, §§2.2 and 5.
The HCM recommendation concerns acute hypotension with obstruction, when fluid administration is insufficient, not routine treatment of all HCM. “Avoid if LV is poor” is a warning about afterload and output, rather than a stand-alone rule that replaces assessment of obstruction and perfusion. AHA 2024 HCM clinical-update slides, slide 22.
5. Dopamine: D1 → β1 → α1, 2–20 µg/kg/min, more arrhythmias than noradrenaline.
The dose-dependent teaching sequence is useful, but dopamine also acts at D2 receptors and the single SVR ↑ arrow does not describe low-dose vasodilation. The 2–20 µg/kg/min strip is a published comparison range, not a fixed receptor-switch schedule or the full product-label range. Dopamine label, §§2.2 and 12; Overgaard and Džavík, table p.1049.
The arrhythmia warning is supported by SOAP II: events occurred in 24.1% with dopamine versus 12.4% with norepinephrine. Overall 28-day mortality did not differ significantly, so the trial did not establish an overall mortality benefit. Norepinephrine remains preferred in septic shock. De Backer et al. SOAP II, NEJM 2010; SSC 2021.
6. Dobutamine: β1-predominant inotropy, 2–20 µg/kg/min, low CO with adequate BP.
The inodilator summary and expected CO increase/SVR reduction are useful. BP → is not guaranteed: pressure may rise or fall, and HR/arrhythmias can increase. The 2–20 µg/kg/min strip matches usual trial infusion rates in the cited label, which starts lower at 0.5–1 µg/kg/min and then titrates. Adequate BP is a useful caution, not a ban on using dobutamine with a separate vasopressor when both are needed. Dobutamine label, clinical pharmacology, warnings and dosing; SSC 2026, inotropes.
7. Milrinone: PDE-III inhibition, 0.375–0.75 µg/kg/min, “often skip load”, RV support and renal-impairment precautions.
PDE3 inhibition, increased output and reduced vascular resistance are supported; hypotension and arrhythmias remain important risks. The maintenance range matches the cited label. The label also specifies a 50 µg/kg loading dose over 10 minutes. “Often skip load” describes an individual clinical decision rather than the label regimen. Renal impairment prolongs elimination and can require lower infusion rates, including below this strip. Milrinone label, pharmacology, precautions and renal dosing.
Milrinone can support RV function and reduce pulmonary vascular resistance. The phrase “great for RV failure” applies only in the appropriate clinical setting: the cause of RV failure and systemic blood pressure matter, and pulmonary hypertension alone is not an indication for an inotrope. Kaplan’s Cardiac Anesthesia, 8th ed., chapter 15, pp.632–633.
8. Levosimendan: calcium sensitiser/K-ATP, 0.05–0.2 µg/kg/min for 24 h, “active metabolite lasts 7–9 days”.
The mechanism and infusion range are supported for the labelled severe decompensated chronic-heart-failure setting; BP may fall and HR may rise as output increases. The 7–9-day statement refers to the duration of effect: haemodynamic effects can persist for up to 7–9 days after a 24-hour infusion. The metabolites have half-lives of about 75–80 hours; the parent drug’s is about one hour. These are different measures. The label contraindicates use with creatinine clearance below 30 mL/min, severe hypotension/tachycardia and significant mechanical filling/outflow obstruction. Simdax SmPC, §§4.2–4.4, 5.1–5.2.
9. Nitroglycerin: NO donor, “0.5–5 µg/kg/min · sublingual / spray OT”, avoid in AS/RV failure.
Predominant venodilation and preload reduction are supported. Despite the HR → and CO → arrows, HR often rises reflexly and output can rise or fall with the starting circulation. IV infusion and sublingual administration use different dosing regimens. The µg/kg/min strip cannot be used as a spray/tablet dose and is not a universal IV starting regimen; the cited US IV label starts at 5 µg/min with non-absorbing tubing and titrates to response. The linked spray contains 400 µg per metered spray. Nitroglycerin IV label, clinical trials and dosing; GTN spray SmPC, §§2 and 4.2.
The AS warning reflects UK product labels, which explicitly list aortic stenosis among contraindications. The “RV failure” warning concerns the danger of low filling pressure/preload dependence and hypotension, rather than every form of RV failure. The actual formulation’s contraindications remain important. PDE5 inhibitors and riociguat are also important nitrate interaction warnings. GTN infusion SmPC, §§4.3–4.5; GTN spray SmPC, §§4.3–4.5.
10. Nitroprusside: arterial and venous dilation, 0.3–2 µg/kg/min, cyanide risk.
The NO-mediated vasodilator mechanism and reductions in preload, SVR and BP are supported. CO ↑ is conditional, not assured; output is variable. Sodium nitroprusside FDA label, §12.1. The dose strip is a low-dose portion of the labelled range: 0.3 µg/kg/min is the starting rate, while 2 µg/kg/min is not a universal maximum. “Short runs” alone does not capture the safety requirements: continuous BP monitoring and adherence to the product’s dose/duration limits are essential. High-rate exposure can cause cyanide toxicity; prolonged treatment, particularly with renal impairment, also risks thiocyanate accumulation. Sodium nitroprusside label, clinical pharmacology, warnings and dosing.
11. Ephedrine: “Indirect α+β”, 3–9 mg IV, tachyphylaxis.
The “Indirect α+β” summary refers to only part of the mechanism: ephedrine combines direct α/β agonism with indirect norepinephrine release. BP, HR and CO usually rise, but the SVR response is variable. The bolus strip corresponds to the UK hydrochloride label, which gives 3–6 mg slowly IV, up to 9 mg per dose and 30 mg cumulatively for spinal/epidural hypotension. A US sulfate label uses 5–10 mg IV with a 50 mg cumulative limit. The formulation and local regimen determine which instructions apply; the two regimens are not interchangeable. Repeated doses may cause tachyphylaxis, making availability of an alternative pressor important. Ephedrine FDA label 2024, §§2.2, 5.2 and 12; Ephedrine UK SmPC, §§4.1–4.2.
12. Isoprenaline: β1/β2 chronotrope, 0.5–5 µg/min, bridge to pacing.
Nonselective β stimulation with increased HR/output and reduced peripheral resistance is supported. The BP ↓ arrow refers to the usual fall in mean and diastolic pressure, while systolic pressure can stay unchanged or rise. The 0.5–5 µg/min range appears in the cited US isoproterenol label for shock/hypoperfusion; it is not the same as a universal bradycardia starting regimen. RCUK 2025 lists 5 µg/min as a starting dose when atropine is ineffective. The bridge concept is reasonable, but pacing must not be delayed in unstable refractory bradycardia; monitoring for arrhythmia and myocardial ischaemia remains essential. The unit is µg/min, not µg/kg/min. Isoproterenol label, §§2.2, 5.1 and 12; RCUK adult ALS 2025, bradycardia.
Guideline update: SSC 2026 compared with SSC 2021
The 2026 Surviving Sepsis Campaign guideline retains norepinephrine as the usual first vasopressor, suggests adding vasopressin with escalating norepinephrine, and adding epinephrine when pressure remains inadequate. It specifically permits norepinephrine or epinephrine first-line when septic shock includes cardiac dysfunction, with tachyarrhythmia favouring norepinephrine and bradyarrhythmia favouring epinephrine.
For cardiac dysfunction with persistent hypoperfusion despite adequate filling and arterial pressure, it suggests dobutamine added to norepinephrine or epinephrine alone. Evidence is insufficient to choose dobutamine over milrinone. It suggests against levosimendan in that septic-shock setting. These recommendations do not make the twelve drugs interchangeable and are not a universal post-bypass algorithm.
For education. Apply the cited sources in their clinical context and follow current local guidance; this material is not patient-specific advice.